New Data Presented at UEGW Confirm Effectiveness and Safety of RESOLOR(R) for Patients With Chronic Constipation (y 2)

In 2006, Movetis secured 49 million Euros in a series 'A' financing from major European and US investors - one of the biggest series 'A' rounds in Europe. These funds are being used to complete the development and registration filing of RESOLOR, and to continue preclinical and clinical development of all other products. Investors include Sofinnova Partners, J&J, Life Sciences Partners, Sofinnova Ventures, KBC Private Equity and KBC Private Equity Fund Biotech, GIMV, Quest for Growth and BIP Investment Partners. Movetis is based in Turnhout, Belgium.

References

(1) J. Tack, G. Tan, L. Vandeplassche. A randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety of prucalopride in patients with chronic constipation. Abstract OP-G-377, UEGW 2007.

(2) P. Pare, S. Ferrazzi, W.G. Thompson, et al. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol 2001;96:3130-7.

(3) IMS Health.

(4) Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004;99:750-9.

Visit http://www.movetis.com/news.aspx to download the press release (Tuesday 30 October 2007, from 14.00 CET)

For further information contact Axon Communications: Ludivine Delattre, Tel: +44-(0)20-8439-9477, ldelattre@axon-com.com; Sarah Griffin, Tel: +44-(0)20-8439-9582, sgriffin@axon-com.com